Impact of Biopsy Proven Liver Fibrosis on Patients Undergoing Evaluation and Treatment for Advanced Heart Failure Surgical Therapies
Copyright © 2023. Published by Elsevier Inc..
There is a paucity of data regarding the impact of liver fibrosis on patients with stage D heart failure (HF). We conducted a retrospective study (January 1, 2017 to December 12, 2020) in patients with stage D HF who underwent liver biopsy as part of their advanced HF therapy evaluation. Baseline characteristics and 1-year outcomes were compared between no- or mild-to-moderate-fibrosis (grade 0 to 2) and advanced-fibrosis (grade 3 to 4) groups. Of 519 patients with stage D HF, 136 who underwent liver biopsy (113 [83%] no or mild-to-moderate fibrosis and 23 [17%] advanced fibrosis) were included. A total of 71 patients (52%) received advanced HF therapies (23 heart transplantation, 48 left ventricular assist devices). One-year mortality was higher among patients with advanced fibrosis (52% vs 18%, p <0.001). Further subgroup analysis suggested a trend toward increased 1-year mortality among patients with advanced fibrosis who underwent advanced therapies (37% vs 13%, p = 0.09). There was a trend of lower likelihood of receiving advanced HF therapies in the advanced-fibrosis group, only 1 heart transplantation and 7 left ventricular assist devices, but it did not reach statistical significance (35% vs 56%, p = 0.06). After adjustment for confounders, degree of liver fibrosis was an independent predictor of mortality (odds ratio 6.2; 95% 1.27 to 30.29, p = 0.02). We conclude that advanced liver fibrosis is common among patients with stage D HF who undergo evaluation for advanced HF surgical therapies and significantly increases 1-year mortality. Further larger studies are needed to support our findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:194 |
|---|---|
| Enthalten in: |
The American journal of cardiology - 194(2023) vom: 01. Mai, Seite 46-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goyal, Amandeep [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.04.2023 Date Revised 26.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjcard.2023.02.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354531573 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354531573 | ||
| 003 | DE-627 | ||
| 005 | 20231226062427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjcard.2023.02.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354531573 | ||
| 035 | |a (NLM)36947946 | ||
| 035 | |a (PII)S0002-9149(23)00080-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goyal, Amandeep |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Biopsy Proven Liver Fibrosis on Patients Undergoing Evaluation and Treatment for Advanced Heart Failure Surgical Therapies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2023 | ||
| 500 | |a Date Revised 26.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a There is a paucity of data regarding the impact of liver fibrosis on patients with stage D heart failure (HF). We conducted a retrospective study (January 1, 2017 to December 12, 2020) in patients with stage D HF who underwent liver biopsy as part of their advanced HF therapy evaluation. Baseline characteristics and 1-year outcomes were compared between no- or mild-to-moderate-fibrosis (grade 0 to 2) and advanced-fibrosis (grade 3 to 4) groups. Of 519 patients with stage D HF, 136 who underwent liver biopsy (113 [83%] no or mild-to-moderate fibrosis and 23 [17%] advanced fibrosis) were included. A total of 71 patients (52%) received advanced HF therapies (23 heart transplantation, 48 left ventricular assist devices). One-year mortality was higher among patients with advanced fibrosis (52% vs 18%, p <0.001). Further subgroup analysis suggested a trend toward increased 1-year mortality among patients with advanced fibrosis who underwent advanced therapies (37% vs 13%, p = 0.09). There was a trend of lower likelihood of receiving advanced HF therapies in the advanced-fibrosis group, only 1 heart transplantation and 7 left ventricular assist devices, but it did not reach statistical significance (35% vs 56%, p = 0.06). After adjustment for confounders, degree of liver fibrosis was an independent predictor of mortality (odds ratio 6.2; 95% 1.27 to 30.29, p = 0.02). We conclude that advanced liver fibrosis is common among patients with stage D HF who undergo evaluation for advanced HF surgical therapies and significantly increases 1-year mortality. Further larger studies are needed to support our findings | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Dalia, Tarun |e verfasserin |4 aut | |
| 700 | 1 | |a Ranka, Sagar |e verfasserin |4 aut | |
| 700 | 1 | |a Sauer, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jinxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Cernik, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Nuqali, Abdulelah |e verfasserin |4 aut | |
| 700 | 1 | |a Chandler, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Parimi, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Majmundar, Monil |e verfasserin |4 aut | |
| 700 | 1 | |a Tayeb, Taher |e verfasserin |4 aut | |
| 700 | 1 | |a Haglund, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Zubair |e verfasserin |4 aut | |
| 700 | 1 | |a Vidic, Andrija |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Bhanu |e verfasserin |4 aut | |
| 700 | 1 | |a Haglund, Nicholas A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of cardiology |d 1958 |g 194(2023) vom: 01. Mai, Seite 46-55 |w (DE-627)NLM000025364 |x 1879-1913 |7 nnns |
| 773 | 1 | 8 | |g volume:194 |g year:2023 |g day:01 |g month:05 |g pages:46-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjcard.2023.02.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 194 |j 2023 |b 01 |c 05 |h 46-55 | ||